Frontlight ResearchEarly access
Metastatic breast cancer trials in China
224 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 4Not yet taking people in ChinaCohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
- Where
- Xi'an
- Age
- 18 years to 85 years
- People
- 40
- Run by
- Yan Xue
See details and how to joinNCT07162259 - Phase 2Not yet taking people in ChinaA Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 150
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07040644 - No phaseTaking peopleRapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
- Where
- Kunming
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Yunnan Cancer Hospital
See details and how to joinNCT07154563 - Phase 2/3Taking peoplePhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
- Where
- Anyang, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Luoyang, Pingxiang, Yinchuan
- Age
- 18 years to 75 years
- People
- 374
- Run by
- Shanghai Pharmaceuticals Holding Co., Ltd
See details and how to joinNCT05744687 - Phase 3Taking peopleRandomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 200
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06255392 - Phase 3Taking peopleClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- Where
- Anyang, Beijing, Bengbu, Changchun, Changsha, Chifeng, Dalian, Dazhou, Fuzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Jiamusi, Jiangmen, Jining, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou
- Age
- 18 years to 75 years
- People
- 246
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT07008976 - Phase 2Not yet taking people in ChinaExploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
- Where
- Beijing
- Age
- 18 years and over
- People
- 155
- Run by
- Beijing 302 Hospital
See details and how to joinNCT06556862 - No phaseTaking peopleExploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 40
- Run by
- QIAO LI
See details and how to joinNCT07117864 - No phaseTaking peopleReal-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Where
- Changsha
- Age
- 18 years and over
- People
- 200
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07073755 - No phaseTaking peoplePET/CT for Trop2 ADC Response Evaluation Cancers
- Where
- Xiamen
- Age
- 18 years and over
- People
- 50
- Run by
- The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07046689 - Phase 2Taking peopleRC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 74
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07065435 - No phaseNot yet taking people in ChinaArtificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer
- Where
- Chongqing
- Age
- 19 years to 85 years
- People
- 900
- Run by
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
See details and how to joinNCT07063667 - No phaseTaking peopleReal-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
- Where
- Changsha
- Age
- 18 years and over
- People
- 300
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT06033287 - Phase 3Not yet taking people in ChinaComparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 474
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07061717 - No phaseEnrolling by invitationEfficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
- Where
- Changchun
- Age
- 18 years to 100 years
- People
- 200
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT06914661 - Phase 2Not yet taking people in ChinaSHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 18
- Run by
- Anhui Provincial Cancer Hospital
See details and how to joinNCT07047443 - Phase 2Not yet taking people in ChinaStudy of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 48
- Run by
- Fudan University
See details and how to joinNCT07041437 - Phase 3Taking peopleA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- Where
- Beijing, Changchun, Changsha, Dalian, Harbin, Hefei, Jinan, Kaifeng, Lanzhou, Nanjing, Puyang, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi'an, Yuncheng, Zhengzhou
- Age
- 18 years to 75 years
- People
- 642
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT07003074 - Phase 1Taking peopleHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 157
- Run by
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT06769425 - Phase 3Taking peopleA Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 378
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT06383767 - Phase 2Taking peopleA Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
- Where
- Shanghai
- Age
- 18 years and over
- People
- 50
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06832202 - Phase 2Taking peoplePyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 63
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07014410 - Phase 3Taking peopleStudy of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
- Where
- Beijing
- Age
- 18 years and over
- People
- 330
- Run by
- BeBetter Med Inc
See details and how to joinNCT06998108 - Phase 3Taking peopleEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- Where
- Beijing
- Age
- 18 years and over
- People
- 880
- Run by
- Shanghai JMT-Bio Inc.
See details and how to joinNCT05838066 - No phaseTaking peopleIntegrin αvβ6-targeted PET in Malignant Tumors
- Where
- Wuhan
- Age
- 18 years to 85 years
- People
- 200
- Run by
- Zhongnan Hospital
See details and how to joinNCT05835570